Stefan Bielack
A5027746254- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Cardiac tumors and thrombi
- FOXO transcription factor regulation
- Lymphoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Vascular Tumors and Angiosarcomas
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Management of metastatic bone disease
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Renal and related cancers
- Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Testicular diseases and treatments
- Medical Imaging and Pathology Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer, Stress, Anesthesia, and Immune Response
- Acute Myeloid Leukemia Research
- Soft tissue tumor case studies
Klinikum Stuttgart
2016-2025
Olgahospital
2016-2025
Klinik und Poliklinik für Kinder- und Jugendmedizin
2004-2024
University Hospital Münster
2014-2024
St Anna Children's Hospital
2002-2023
German Cancer Research Center
2023
Hopp Children's Cancer Center Heidelberg
2023
Heidelberg University
2003-2023
Sabin Vaccine Institute
2023
University of Cincinnati
2023
PURPOSE: To define prognostic factors for response and long-term outcome a wide spectrum of osteosarcomas, extending well beyond those the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total 1,702 consecutive newly diagnosed patients high-grade osteosarcoma trunk or limbs registered into neoadjuvant studies Cooperative Osteosarcoma Study Group before July 1998 were entered an analysis demographic, tumor-related, treatment-related variables,...
To define prognostic factors for response and long-term outcome a wide spectrum of osteosarcomas, extending well beyond those the typical young patient with seemingly localized extremity disease.
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into biology. Here we present comprehensive analysis of genetic alterations in pan-cancer cohort including 961 tumours from children, adolescents, young adults, comprising 24 distinct molecular cancer. Using standardized workflow, identified marked terms mutation frequency significantly mutated genes comparison previously analysed adult cancers....
To determine demographic data and define prognostic factors for long-term outcome in patients presenting with high-grade osteosarcoma of bone clinically detectable metastases at initial presentation.Of 1,765 newly diagnosed, previously untreated osteosarcomas registered the neoadjuvant Cooperative Osteosarcoma Study Group studies before 1999, 202 (11.4%) had proven diagnosis therefore were enrolled onto an analysis demographic-, tumor-, treatment-related variables, response, survival. The...
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Purpose To evaluate the impact of patient, tumor, and treatment-related factors on outcome in unselected patients with recurrent osteosarcoma. Patients Methods Five hundred seventy-six consecutive who had achieved a first complete surgical remission (CR) during combined-modality therapy neoadjuvant Cooperative Osteosarcoma Study Group (COSS) protocols then developed osteosarcoma were analyzed (median time from biopsy to relapse, 1.6 years; range, 0.1 14.3 years). There 501 metastases, 44...
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European American Osteosarcoma Study (EURAMOS)-1 collaboration of four study groups aiming to improve outcomes this rare disease by facilitating randomised controlled trials.Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade in which case complete surgical resection at all sites was deemed be possible. A three-drug combination methotrexate, doxorubicin...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response preoperative (≥10% viable tumour) improved event-free survival in with high-grade osteosarcoma.EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting newly diagnosed, resectable, osteosarcoma aged 40 years or younger were eligible randomisation. Patients randomly assigned (1:1) receive either cisplatin,...
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.
Abstract Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has historically complicated driver gene discovery. Here we sequence exomes 31 and decipher their evolutionary landscape by inferring clonality the individual mutation events. Exome findings interpreted in context SNP array data from replication set 92 tumours. We identify 14 genes as main drivers, some were formerly unknown osteosarcoma. None drivers is clearly responsible for majority even...
Four international study groups undertook a large in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based histological response.Patients with osteosarcoma aged ≤40 years were treated MAP regimen, comprising pre-operatively 5-week cycles cisplatin 120 mg/m(2), doxorubicin 75 methotrexate 12 g/m(2) × 2 (MAP) and post-operatively further just MA. Patients after surgery. Those ≥10% viable...
Abstract Background The prognosis in patients with relapsed Ewing sarcoma is unfavorable. Our investigation identifies factors predicting for the outcome following relapse. Procedure We analyzed type of relapse, time to relapse and overall survival after (OSr) 714 first recurrence. All had been treated within Cooperative Sarcoma Studies (CESS) 81 or 86, European Intergroup CESS (EICESS 92). OSr was calculated from diagnosis last follow‐up death. Results Median primary disease 2.2 years (mean...